Related Experiment Video
Updated: Jul 17, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against
Hongtao Li1, Aurelie Dutuor, Lihua Tao
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
Purpose:
We recently constructed an oncolytic virus from type 2 herpes simplex virus (HSV-2) that selectively targets and kills tumor cells with an activated Ras signaling pathway. Designated FusOn-H2, this virus has shown several discrete killing mechanisms. Here, we evaluated the antitumor immune responses after FusOn-H2-mediated virotherapy in a syngeneic murine neuroblastoma model.
Experimental Design:
We directly injected FusOn-H2 into established tumors and then measured its antitumor effect and the accompanying tumor-specific immune responses. Several oncolytic HSVs constructed from HSV-1 were included in the same experiments for comparisons.
Results:
Our data show that tumor destruction by FusOn-H2 in vivo induces potent antitumor immune responses in this syngeneic neuroblastoma model. The elicited cellular immunity not only eradicated neuroblastoma cells in vitro but also inhibited the growth of tumors at sites distant from the virus injection site. Moreover, adoptive transfer of splenocytes from mice receiving virotherapy to naïve mice resulted in a measurable antitumor effect.
Conclusion:
We conclude that the ability of FusOn-H2 to induce tumor-specific cellular immunity expands the oncolytic repertoire of this virus and increases the likelihood that its use in patients would produce significant therapeutic benefits.
Insights
FusOn-H2, an oncolytic herpes simplex virus type 2 (HSV-2), effectively triggers potent antitumor immune responses in neuroblastoma models. This viral therapy demonstrates efficacy against distant tumors and enhances the virus
Area of Science:
- Oncolytic virotherapy
- Immunology
- Cancer research
Background:
- Oncolytic viruses selectively target and destroy cancer cells.
- Herpes simplex virus type 2 (HSV-2) can be engineered for oncolytic applications.
- Ras signaling pathway activation is a target for cancer therapies.
Purpose of the Study:
- To evaluate antitumor immune responses induced by FusOn-H2, an engineered HSV-2 oncolytic virus.
- To assess the efficacy of FusOn-H2 in a syngeneic murine neuroblastoma model.
- To compare FusOn-H2 with other oncolytic herpes simplex viruses (HSVs).
Main Methods:
- Direct intratumoral injection of FusOn-H2 into established neuroblastoma tumors.
- Measurement of antitumor effects and associated immune responses.
- Comparative analysis with oncolytic HSVs derived from HSV-1.
Main Results:
- FusOn-H2 administration induced robust antitumor immune responses in vivo.
- The elicited cellular immunity demonstrated efficacy against neuroblastoma cells in vitro.
- Virotherapy resulted in inhibition of tumor growth at distant sites and measurable antitumor effects via adoptive splenocyte transfer.
Conclusions:
- FusOn-H2 effectively induces tumor-specific cellular immunity.
- This immune response expands the therapeutic potential of FusOn-H2.
- The findings suggest significant therapeutic benefits for patients treated with FusOn-H2.
Related Concept Videos
01:27Tumor Immunotherapy
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...